The 2022 ASCO Genitourinary Cancers Symposium kicked off this week. On this episode, we’ll hear about two studies presented at the meeting: one, focused on a genetic risk score that may aid in identifying men with high vs low lifetime risks of developing metastatic prostate cancer or dying from prostate cancer; and the second, about a trial that tested the efficacy of combination immunotherapy and tyrosine kinase inhibitor therapy for renal cell carcinoma.

Coverage of stories discussed this week on ascopost.com:

Comprehensive Genetic Risk Score May Predict Risk of Developing Metastatic Prostate Cancer or Death From Prostate Cancer Across Diverse Populations

To listen to more podcasts from ASCO, visit asco.org/podcasts.